DPDavid Pépin

David Pépin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Pépin has a total of 331 co-authors. Here are the top co-authors by number of shared publications:

  • Nicholas Nagykery

    Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Department of Surgery, Harvard Medical School, Boston, USA

    13 shared publications
  • Marie-Charlotte Meinsohn

    Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, Massachusetts, USA

    12 shared publications
  • Maeva Chauvin

    Pediatric Surgical Research Laboratories, Massachusetts General Hospital , Boston, MA

    9 shared publications
  • Patricia K. Donahoe

    Pediatric Surgical Research Laboratories, Massachusetts General Hospital

    8 shared publications
  • Patricia K Donahoe

    Pediatric Surgical Research Laboratories, Massachusetts General Hospital , Boston, MA

    7 shared publications
  • Aki Kashiwagi

    Pediatric Surgical Research Laboratories, Massachusetts General Hospital , Boston, MA

    6 shared publications

Latest Publications

  • Distinct metabolomic profiles in lean and non-lean polyendocrine metabolic ovarian syndrome

    by Stylianos Vagios, Alana Mermin-Bunnell, Christopher K. Arkfeld, Alexa M. Sassin, Kaitlyn James, Irene Souter, Frida Polli, David Pepin

  • Open Access

    Cancer-associated mesothelial cells drive immune escape and therapy resistance in ovarian cancer

    by Maeva Chauvin, Julien Roche-Prellezo, Virginie Lafont, Henri-Alexandre Michaud, Estelle Tromelin, Robin Michel, Clara Freixinos, Marie-Charlotte Meinsohn, Pierre-Emmanuel Colombo, Nathalie Bonnefoy, et al.

    Background: Cancer-associated mesothelial cells (CAMCs) are key modulators of the ovarian tumor microenvironment, contributing to tumor growth and immune evasion. Mesothelial cells (MCs) maintain peritoneal homeostasis and immune surveillance and represent the first point of contact during abdominal dissemination of ovarian cancers. Yet, their role in ovarian tumor immunity remains poorly understood. Methods: Lineage tracing, 3D models, and spatial transcriptomic profiling were used to characterize CAMC origin, localization, and phenotypic transitions during ovarian cancer progression. Multiplex cytokine panels were used to define the cytokine profiles associated with MC transformation into CAMCs. Functional studies were conducted in syngeneic ovarian cancer mouse models to assess the impact of CAMCs on tumor growth and response to immunotherapy. In parallel, CAMC-driven changes in immune cell phenotype and functional state within the tumor microenvironment were characterized. Results: We demonstrate that CAMCs originate from peritoneal MCs, populate the tumor surface, and progressively infiltrate the tumor core while undergoing a phenotypic transition toward a fibroblast-like phenotype. We characterize the function of an unrecognized CAMC signature marked by SERPINB2 + expression and a combination of markers absent in normal MCs. CAMC Serpinb2+ cells have reduced expression of pro-inflammatory cytokines (IL-2, IL-7, IL-12, IL-15) and increased expression of IL-10, TGFβ1, and CCL17 compared with normal MCs. Functionally, the presence of CAMC Serpinb2+ cells correlates with accelerated tumor growth, reduced CD4 + T and B cell infiltration, an expanded Treg population, and ultimately resistance to combination immunotherapy in a syngeneic mouse model of ovarian cancer. Conclusions: These findings identify CAMCs as central regulators of immune suppression in ovarian cancer and reveal a distinct SERPINB2 + immunosuppressive CAMC state associated with tumor progression and immunotherapy resistance. Targeting CAMCs may represent a promising therapeutic strategy to restore antitumor immunity and improve responses to current ovarian cancer treatments and immunotherapies.

  • Open Access

    Cancer-Associated Mesothelial Cells Drive Immune Escape and Therapy Resistance in Ovarian Cancer

    by Maeva Chauvin, Julien Roche-Prellezo, Virginie Lafont, Henri-Alexandre Michaud, Estelle Tromelin, Robin Michel, Clara Freixinos, Marie-Charlotte Meinsohn, Pierre-Emmanuel Colombo, Nathalie Bonnefoy, et al.

    Cancer-associated mesothelial cells (CAMCs) are key modulators of the ovarian tumor microenvironment, contributing to tumor growth an immune evasion. Normal mesothelial cells play a role in peritoneal homeostasis and immune surveillance and represent the first point of contact during abdominal dissemination of ovarian cancers. Yet, their role in ovarian tumor immunity remains poorly understood. Here, we map the cellular states, spatial organization, and immune functions of CAMCs across ovarian cancer progression. Using lineage tracing and spatial transcriptomics, we demonstrate that CAMCs originate from mesothelial cells at the tumor surface and can progressively infiltrate the tumor core, undergoing a phenotypic transition towards fibroblast-like and immunosuppressive states. We characterize the function of an unrecognized CAMC subtype marked by SERPINB2+ expression, and a combination of markers absent in normal mesothelial cells. CAMCSerpinb2+ cells have reduced expression of pro-inflammatory cytokines (IL-2, IL-7, IL-12, IL-15) and increased expression of IL-10, TGFB1, and CCL17, promoting regulatory T cell recruitment and tolerogenic CD4+ T cell responses. Functionally, CAMCSerpinb2+ accelerate tumor growth, reduce CD4+ T and B cell infiltration, and expand Treg populations, ultimately leading to immunotherapy resistance. Together, our findings identify CAMCs as a potential therapeutic target in peritoneal carcinomatosis and as a means of restoring sensitivity to current treatments.

  • Open Access

    Gene therapy delivery of anti-Müllerian hormone in prepubertal female domestic cats induces long-term sterilization

    by Philippe Godin, Nicholas Nagykery, Natalie Sicher, Julie L. Barnes, Amy G. Miller, Christina Bunner, Amy K. Thompson, Motohiro Kano, Guangping Gao, Dan Wang, et al.

    The uncontrolled reproduction of free-roaming domestic cats exacerbates their welfare challenges and the ecological pressure they exert on wildlife populations. Because of logistic and economic constraints, surgical sterilization alone cannot scale to control the reproduction of the hundreds of millions of intact cats worldwide. Herein, we report that the single administration of an adeno-associated viral vector delivering an anti-Müllerian hormone transgene to prepubertal cats can fully prevent pregnancy once females reach adulthood. Treated kittens were closely monitored for up to 21 months to assess long-term health, transgene expression, reproductive hormones, and reproductive function. The intramuscular injection was well tolerated and did not impact physical growth. The sustained expression of anti-Müllerian hormone did not impact spermatogenesis in males. However, it induced sterility in mated females by preventing breeding-induced ovulation and increases in progesterone associated with luteal phases, resulting in safe and potentially lifetime sterilization in the female domestic cat.


  • Anti-Müllerian hormone ameliorates uterine DNA damage response and prevents pregnancy complications in doxorubicin-treated mice

    by Ngoc Minh Phuong Nguyen, Alana M Mermin-Bunnell, Karine de Mattos, Josephine Cleverdon, Motohiro Kano, Maeva Chauvin, Philippe Godin, Aki Kashiwagi, Thy Duong, Nicholas Nagykery, et al.

    Anti-Müllerian hormone is a promising fertoprotective agent, demonstrating particularly strong efficacy against doxorubicin-induced ovarian toxicity. However, the impact of chemotherapy on the uterus, and the potential benefits of anti-Müllerian hormone in this context, remain poorly understood. In this study, we characterized doxorubicin-induced uterine damage and assessed the fertoprotective effect of anti-Müllerian hormone co-treatment in mice. Acutely, doxorubicin treatment caused the accumulation of DNA damage in multiple uterine cell-types, including the myometrium, as evidenced by both increased γ-H2AX staining and upregulation of Cdkn1a, Trp53, and other downstream Trp53 pathway targets, both at the mRNA and protein levels. Anti-Müllerian hormone co-treatment counteracted these effects by reducing γ-H2AX-positive DNA damage lesion accumulation and by suppressing Trp53 and its downstream pathway. Furthermore, anti-Müllerian hormone co-treatment significantly reduced the incidence of doxorubicin-induced labor dystocia, a complication of parturition, in pregnancies following chemotherapy treatment. These findings suggest that, in addition to ovarian protection, anti-Müllerian hormone may have benefits in preserving myometrial integrity and long-term uterine function following chemotherapy, further supporting its therapeutic potential for fertility preservation in cancer patients receiving chemotherapy.


  • Anti-Müllerian hormone induces a reversible quiescence-associated secretory phenotype in preantral follicles

    by Marie-Charlotte Meinsohn, Josephine Cleverdon, Alana M Mermin-Bunnell, Karine de Mattos, Phoebe May, Aki Kashiwagi, Rhian Stavely, Nicholas Nagykery, Diane Saunders, Elizabeth L Tsui, et al.

    Anti-Müllerian hormone is a factor secreted by granulosa cells of growing follicles that regulates many aspects of ovarian function, including primordial follicle activation and early follicle development through inhibitory feedback. Treatment with exogenous anti-Müllerian hormone at supraphysiological levels can inhibit follicular development and prevent ovulation in mice, rats, and cats. Single-cell transcriptomic analysis of ovaries from mice treated postnatally with anti-Müllerian hormone identified a distinct quiescence signature in granulosa cells. Herein, we further characterized the anti-Müllerian hormone -induced quiescent cell state and drew parallels to developmental senescence by describing a reversible “quiescence-associated secretory phenotype.” This state was characterized by the induction of several hallmarks of senescence, including inhibition of proliferation (reduced KI67), upregulation of markers of senescence (Cdkn1a, Fn1, Cebpb, Timp3), and chemokines and their receptors (Cxcl14, Cxcl12, Ccl12, Ccl21, Cxcr2). However, quiescence-associated secretory phenotype did not recapitulate other senescence hallmarks, such as activation of beta-galactosidase activity or permanent exit from the cell cycle. Similar to classical senescence, we found that anti-Müllerian hormone induced quiescence-associated secretory phenotype, in part, through the upregulation of cyclin-dependent kinase inhibitors (Cdkn1a, Cdkn1b, and Cdkn1c) in granulosa cells and oocytes of mouse and human ovaries. Finally, we showed that the quiescence-associated secretory phenotype state could be reversed within a month of discontinuing anti-Müllerian hormone treatment. This recovery was marked by the return of growing primary, secondary, and antral follicles. In conclusion, these data suggest that anti-Müllerian hormone can pause follicle development by inducing quiescence-associated secretory phenotype, a reversible senescent-like state, which may benefit fertility preservation.


  • Open Access

    FSTL3 is a biomarker of poor prognosis and associated with immunotherapy resistance in ovarian cancer

    by Maeva Chauvin, Estelle Tromelin, Julien Roche-Prellezo, Hyshem H. Lancia, Marie-Charlotte Meinsohn, Caroline Coletti, Ngoc Minh Phuong Nguyen, Virginie Lafont, Henri-Alexandre Michaud, Ranjan Mishra, et al.

    High-grade serous ovarian carcinoma (HGSOC) is associated with high mortality rates due to late-stage diagnosis and limited treatment options. We investigated the role of FSTL3 in ovarian cancer progression both as a prognostic biomarker and as a potential therapeutic target. We measured levels of follistatin (FST) and follistatin-like 3 (FSTL3) in 96 ovarian cancer patient ascites samples and found that FSTL3 overexpression was more predominant than FST and associated with poorer survival outcomes. Mice implanted with an HGSOC syngeneic cell line bearing common alterations in ovarian cancer (KRASG12 V, P53R172H, CCNE1oe, AKT2oe) had increasing levels of FST and FSTL3 in serum during tumor growth. Further alteration of this model to generate a knockout of FST (KPCA.FSTKO) and an overexpression of human FSTL3 (KPCA.FSTKO_hFSTL3) revealed that FSTL3 expression was associated with a more fibrotic tumor microenvironment, correlating with an increased abundance of cancer-associated myofibroblasts (myCAFs), and cancer cells with a more mesenchymal phenotype. Tumors overexpressing FSTL3 also had significantly less immunocyte infiltration, reduced intratumoral T-cell abundance, and increased CD8+ T cell exhaustion. FSTL3 overexpression completely abrogated tumor response to PPC treatment (Prexasertib combined with PD-1 and CTLA-4 blockade) compared to controls, suggesting that FSTL3 may be involved in immunotherapy resistance. In conclusion, this study suggests a role for FSTL3 as a prognostic marker and as therapeutic target in HGSOC, where it may play a role in promoting a mesenchymal tumor phenotype, maintaining an immunosuppressive tumor microenvironment, and driving immunotherapy resistance. Graphical Abstract


  • Anti-Müllerian hormone binds heat shock protein glucose-regulated protein 78 in human follicular fluid

    by Caitlin R. Sacha, Nicholas Nagykery, Marie-Charlotte Meinsohn, Karine de Mattos, James A. Howard, Hadi Ramadan, Evelyn Minis, LiHua Zhang, Victoria Fitz, Karissa Hammer, et al.

    Purpose Anti-Müllerian hormone (AMH) regulates key steps in folliculogenesis, yet unlike other TGF-β family members, no soluble AMH-binding proteins have been identified. We hypothesized that AMH may bind shuttling proteins in human follicular fluid (FF). Methods Discarded pooled FF was collected from women undergoing oocyte retrieval at an academic fertility center. AMH-binding soluble proteins in FF were co-immunoprecipitated with AMH, identified by mass spectrometry, and their association was validated by western blot. We characterized the spatiotemporal expression of candidate binding protein glucose-regulated protein 78 (GRP78) in the mouse ovary across the cycle by immunohistochemistry. We used enzyme-linked immunoassay (ELISA) to measure AMH and GRP78 concentrations in patient FF. We used transient transfections in Chinese hamster ovary (CHO) cells to understand the interaction between AMH and GRP78. Results Co-immunoprecipitation of AMH in FF identified multiple soluble AMH-binding candidates in the heat-shock protein family, which was confirmed by reciprocal co-immunoprecipitation. We found that GRP78, the most abundant candidate, was enriched in antral follicles of mice at estrus and was present in higher concentrations in human FF than AMH. Finally, we found that AMH overexpression increased endoplasmic reticulum stress and induced GRP78 expression in CHO cells; further ectopic overexpression of GRP78 facilitated the secretion of AMH. Conclusion This work describes AMH-binding protein candidates identified in human FF and suggests that GRP78 may chaperone AMH during secretion and remain bound in FF. Further study is warranted to understand how heat shock proteins may modulate other biological aspects of AMH and their effects on fertility.


  • Open Access

    Hippo Signaling Is Essential for the Maintenance of Zona Glomerulosa Cell Fate in the Murine Adrenal Cortex

    by Nour Abou Nader, Natalia Jakuc, Marie-Charlotte Meinsohn, Laureline Charrier, Laurence Banville, Julie Brind’aMour, Marilène Paquet, Guillaume St-Jean, Derek Boerboom, Junhao Mao, et al.

    Cells of the zona glomerulosa (zG), the outermost zone of the adrenal cortex, secrete aldosterone and transdifferentiate into glucocorticoid-producing cells of the zona fasciculata (zF) during adrenal homeostasis. However, our understanding of the signaling pathways mediating zG cell maintenance or their transdifferentiation into zF cells is incomplete. Hippo is a major pathway that regulates cell proliferation/differentiation during embryogenesis and postnatal tissue homeostasis. Hypothesizing that Hippo signaling could be involved in zG cell maintenance or transdifferentiation, we generated a mouse model in which the two main kinases of the Hippo signaling cascade large tumor suppressor homolog kinases 1/2 (Lats1 and Lats2) are specifically inactivated in zG cells. Here we show that loss of function of Lats1 and Lats2 impairs zG steroidogenesis and leads to zG cell transdifferentiation into cells sharing characteristics with chondroblasts/osteoblasts rather than zF cells. Furthermore, we demonstrate that this phenotype can be rescued by the concomitant inactivation of the transcriptional coactivators Yes-associated protein (Yap) and transcriptional coactivator with PDZ-binding motif (Taz) with Lats1 and Lats2. Finally, we show that expression of a constitutively active form of YAP (YAP5SA) in zG cells does not alter their fate as severely as the loss of Lats1 and Lats2 but leads to adrenal hyperplasia. Together, these findings highlight the critical role of Hippo signaling in maintaining zG cell fate and function and provide key insights into broader mechanisms underlying cellular differentiation.


  • Oxidation of retromer complex controls mitochondrial translation

    by Junbing Zhang, Yousuf Ali, Harrison Byron Chong, Pei-Chieh Tien, James Woods, Carolina Noble, Tristan Vornbäumen, Zehra Ordulu, Anthony P. Possemato, Stefan Harry, et al.

    Reactive oxygen species (ROS) underlie human pathologies including cancer and neurodegeneration1,2. However, the proteins that sense ROS levels and regulate their production through their cysteine residues remain ill defined. Here, using systematic base-editing and computational screens, we identify cysteines in VPS35, a member of the retromer trafficking complex3, that phenocopy inhibition of mitochondrial translation when mutated. We find that VPS35 underlies a reactive metabolite-sensing pathway that lowers mitochondrial translation to decrease ROS levels. Intracellular hydrogen peroxide oxidizes cysteine residues in VPS35, resulting in retromer dissociation from endosomal membranes and subsequent plasma membrane remodelling. We demonstrate that plasma membrane localization of the retromer substrate SLC7A1 is required to sustain mitochondrial translation. Furthermore, decreasing VPS35 levels or oxidation of its ROS-sensing cysteines confers resistance to ROS-generating chemotherapies, including cisplatin, in ovarian cancer models. Thus, we identify that intracellular ROS levels are communicated to the plasma membrane through VPS35 to regulate mitochondrial translation, connecting cytosolic ROS sensing to mitochondrial ROS production.